Tay-Sachs Disease

Tay Sachs Disease — scientific infographic poster

Overview and Epidemiology

Tay-Sachs disease is a fatal autosomal recessive lysosomal storage disorder caused by mutations in the HEXA gene on chromosome 15q23, which encodes the alpha-subunit of beta-hexosaminidase A (Hex-A). Without functional Hex-A, the ganglioside GM2 accumulates progressively within neuronal lysosomes, leading to relentless neurodegeneration and, in the classic infantile form, death before age five. The disease was independently described in the 1880s by British ophthalmologist Warren Tay, who noted the characteristic cherry-red spot on fundoscopy in 1881, and by American neurologist Bernard Sachs, who in 1887 described the full clinical and pathological syndrome — then called "amaurotic familial idiocy" — recognizing its familial pattern and Jewish ancestry clustering.

In the general population, carrier frequency is approximately 1 in 300. Among Ashkenazi Jews, the carrier rate rises dramatically to approximately 1 in 30 — roughly ten times higher — reflecting a founder effect from a small ancestral population. Elevated carrier frequencies are also documented in French Canadians of Quebec, Cajun communities of Louisiana, and individuals of Irish (Celtic) descent. In populations where targeted carrier screening programs have been implemented, particularly the Ashkenazi Jewish community beginning in the 1970s, the incidence of the devastating infantile form has fallen dramatically — one of the great successes of population genetic screening in medicine.

Three clinical forms are recognized based on the amount of residual Hex-A activity and the age of onset: classic infantile (the most severe and most common), juvenile (subacute), and adult or late-onset Tay-Sachs (LOTS). All share the same underlying enzyme deficiency, but the degree of residual enzyme activity correlates inversely with disease severity and inversely with age of onset. The disease remains without an approved disease-modifying treatment, though gene therapy clinical trials are underway.

Back to Table of Contents

Pathophysiology: HEXA Gene and GM2 Ganglioside

The HEXA gene spans approximately 35 kilobases on chromosome 15q23 and encodes the 529-amino-acid alpha-subunit of beta-hexosaminidase A. Hex-A is an alpha-beta heterodimer: two subunits encoded by distinct genes (HEXA for alpha, HEXB for beta) assemble in the endoplasmic reticulum, traffic through the Golgi apparatus, and are delivered to the lysosome via the mannose-6-phosphate receptor pathway. Within the lysosome, Hex-A cleaves the terminal N-acetylgalactosamine residue from GM2 ganglioside, a glycolipid that is a normal structural component of neuronal cell membranes and is continuously generated during membrane turnover. This cleavage step is an obligate part of the GM2 catabolism pathway; without it, GM2 has no alternative route for degradation and accumulates irreversibly.

Three isoforms of beta-hexosaminidase exist in human tissues: Hex-A (alpha-beta heterodimer, active on GM2 ganglioside), Hex-B (beta-beta homodimer, active on other substrates but not GM2 ganglioside), and Hex-S (alpha-alpha homodimer, unstable and minimally active). In Tay-Sachs disease, the alpha-subunit is non-functional; Hex-B activity is therefore preserved and often elevated (since the beta-subunit continues to be produced and forms beta-beta homodimers). This distinction is diagnostically important: total hexosaminidase activity (Hex-A + Hex-B) may be normal or even elevated in Tay-Sachs, while the Hex-A fraction specifically is absent or severely reduced. The ratio of Hex-A to total hexosaminidase is the key diagnostic metric.

GM2 ganglioside accumulation begins prenatally in neurons and accelerates after birth as neuronal activity and membrane turnover increase. The ganglioside accumulates within lysosomes, causing progressive lysosomal swelling, disruption of axonal transport, mitochondrial dysfunction, activation of apoptotic pathways, and ultimately neuronal death. The process is highly selective for neurons — particularly large neurons such as motor neurons and the ganglion cells of the retina — because neuronal membranes are exceptionally rich in gangliosides compared to other cell types. The liver, spleen, and other visceral organs are largely spared, in contrast to Gaucher or Niemann-Pick disease, because those organs' macrophages generate far less GM2 substrate.

Back to Table of Contents

Three distinct inherited disorders share the same pathological endpoint — lysosomal GM2 ganglioside accumulation causing neurodegeneration — but arise from mutations in three different genes. Together they are called the GM2 gangliosidoses, and distinguishing between them requires enzyme activity profiling rather than clinical criteria alone, because the infantile forms are clinically indistinguishable.

Sandhoff disease (also called GM2 gangliosidosis type II, or Hexosaminidase A and B deficiency) is caused by loss-of-function mutations in the HEXB gene, which encodes the beta-subunit shared by both Hex-A and Hex-B. Because Hex-A requires a functional beta-subunit to form its alpha-beta heterodimer, and Hex-B is itself a beta-beta homodimer, Sandhoff disease abolishes activity of both Hex-A and Hex-B simultaneously. Total hexosaminidase activity is essentially absent. Clinically, infantile Sandhoff disease is nearly identical to infantile Tay-Sachs — cherry-red spot, acoustic hyperekplexia, progressive neurodegeneration, death by age four. However, Sandhoff disease additionally causes mild accumulation of globoside (another hexosaminidase substrate) in visceral organs, occasionally producing mild hepatosplenomegaly — a finding absent in Tay-Sachs. Sandhoff is not enriched in the Ashkenazi Jewish population, but it is not evenly spread either: community screening studies found carriers in about 1 in 7 people of the Maronite community of Cyprus (one mutation, a deletion at nucleotide 76, predominating), about 1 in 15 in communities of northern Saskatchewan in Canada (against about 1 in 57 estimated from the global 1000 Genomes sample in the same study), and a cluster with a high rate of infantile Sandhoff disease in a region of Córdoba, Argentina, where a single splice-site mutation accounted for 30 of 31 disease alleles examined. The site has a separate page on Sandhoff disease.

AB-variant GM2 gangliosidosis is the rarest of the three, caused by mutations in the GM2A gene encoding the GM2 activator protein (GM2AP). GM2AP is a small lipid-transfer protein that binds the GM2 ganglioside substrate and presents it to Hex-A in a form the enzyme can process — Hex-A cannot efficiently cleave GM2 from intact ganglioside micelles without this activator. In the AB-variant, Hex-A enzyme activity is measurably normal when assayed with the synthetic substrate used in routine laboratory testing (which does not require GM2AP), but the enzyme cannot act on natural GM2 ganglioside in vivo. This creates a diagnostic trap: enzyme assay is falsely normal; only specialized activator protein assays, GM2A gene sequencing, or thin-layer chromatography of stored lipid can identify the correct diagnosis.

Back to Table of Contents

Classic Infantile Tay-Sachs

The classic infantile form is the most common and most severe presentation of Tay-Sachs disease. Affected infants are born after an uncomplicated pregnancy and appear entirely normal at birth, passing newborn screening and early developmental milestones. The first parental concern typically arises between three and six months of age, when the child seems to stop progressing or parents notice subtle regression — the baby who was beginning to reach for objects loses interest, the social smile becomes less frequent, and early motor development plateaus.

The exaggerated startle response to sound (acoustic hyperekplexia) is among the earliest and most pathognomonic clinical signs, often recognizable before other neurological abnormalities become obvious. An affected infant will startle with marked, exaggerated whole-body stiffening and extension in response to sudden loud noises — a response far greater than the normal Moro response and one that does not habituate with repeated stimulation (unlike the normal startle, which diminishes). Parents frequently notice this first as an unusually intense reaction to sounds in the home environment.

The cherry-red spot on fundoscopy is a classic finding, typically visible between six and twelve months. It arises because GM2 ganglioside deposits in the cytoplasm of retinal ganglion cells (which are densest at the macula) make the surrounding retina appear pale white or gray. The central macula, which normally appears slightly reddish due to its rich vascular supply and thin ganglion cell layer, stands out by contrast as a vivid red spot surrounded by pallid retina. While highly associated with Tay-Sachs disease, the cherry-red spot is not exclusive to it — it is also seen in Niemann-Pick disease types A and C, GM1 gangliosidosis, metachromatic leukodystrophy, Farber disease, and sialidosis, and rarely in central retinal artery occlusion.

The clinical course after six months follows a stereotyped, relentless trajectory of neurological decline. Hypotonia gives way to increasing spasticity; developmental milestones that were achieved are lost (developmental regression); seizures emerge, typically between twelve and eighteen months, initially as infantile spasms or myoclonic jerks and evolving to multiple refractory seizure types. Vision loss progresses to blindness from retinal ganglion cell destruction and optic atrophy. Cortical deafness ensues despite intact cochlear function. Decorticate and decerebrate posturing develop. By the third to fourth year, most children are in a vegetative state, requiring tube feeding and mechanical ventilation. Death typically occurs between two and five years of age, most often from respiratory failure, aspiration pneumonia, or intercurrent infection. There is no hepatosplenomegaly — the viscera are spared.

Back to Table of Contents

Juvenile and Adult-Onset Forms

Juvenile (subacute) Tay-Sachs disease presents in children between approximately two and ten years of age and follows a slower but ultimately fatal course. Unlike the classic infantile form, early development is normal, and the condition often comes to attention through school difficulties, clumsiness, or behavioral changes. Cerebellar ataxia and dysarthria are typically the earliest neurological signs. Cognitive decline and learning difficulties progress over months to years. Seizures occur in most patients but may not appear until years after onset. Visual deterioration is present but sometimes milder than in the infantile form; the cherry-red spot may be absent or less vivid. Death typically occurs in the teens or early twenties.

Adult or late-onset Tay-Sachs disease (LOTS) is a clinically distinct and widely underrecognized syndrome that can present deceptively as psychiatric illness or motor neuron disease. Onset typically occurs from the late teens into the thirties. Patients retain significant residual Hex-A activity (higher than infantile or juvenile patients) and survive into adulthood, often for decades, but with progressive disability.

The neurological picture in adult Tay-Sachs is dominated by two overlapping phenotypes. The first is a progressive lower motor neuron disorder resembling spinal muscular atrophy: proximal limb weakness, fasciculations, reduced reflexes, and muscle atrophy from anterior horn cell degeneration. Upper motor neuron signs (spasticity, hyperreflexia) may coexist, giving a mixed upper and lower motor neuron picture that can superficially mimic amyotrophic lateral sclerosis (ALS). Cerebellar signs — ataxia, dysarthria, dysmetria — are frequently present. The second phenotype is psychiatric: adult Tay-Sachs frequently presents with psychosis, mania, depression, or a schizophrenia-like syndrome as the earliest manifestation, sometimes years before neurological signs appear. Because the psychiatric features are prominent and the diagnosis is rarely suspected in adults, patients with adult Tay-Sachs are routinely misdiagnosed with schizophrenia or bipolar disorder for years or even decades. The authors of a 21-patient series wrote that the condition belongs on the list of possibilities for people with speech, gait and balance problems and for people with psychiatric disorders, even before clear neurological signs appear; treatment-resistant psychosis with cerebellar signs, lower motor neuron features, or a family history suggesting storage disease is the setting in which a Hex-A assay is used. Unlike the infantile form, adult Tay-Sachs does not typically cause cherry-red spot or epilepsy as prominent features.

A study of 21 people with late-onset Tay-Sachs (Neudorfer and colleagues, 2005) gives a picture in numbers: the average age at onset was 18.1 years, and diagnosis was often delayed by about 8 years (average age at diagnosis 27.0). Balance problems and trouble climbing stairs were the most common first complaints. Every one of the 18 patients who had brain scans showed marked shrinkage of the cerebellum (cerebellar atrophy), whatever the disease stage. The G269S mutation was found on at least one copy of the gene in 19 of the 21 patients; the one patient with two copies had a later onset (age 36) and slower progression. Two non-Jewish siblings with a different gene combination had a course dominated by psychiatric problems.

Back to Table of Contents

Diagnosis: Enzyme Assay and Genetic Testing

The diagnostic cornerstone of Tay-Sachs disease is measurement of beta-hexosaminidase A (Hex-A) enzyme activity in peripheral blood leukocytes or serum. In affected individuals, Hex-A activity is markedly reduced or absent while total hexosaminidase activity (Hex-A + Hex-B) is preserved or even elevated, reflecting intact Hex-B (beta-beta homodimer). The critical metric is the ratio of Hex-A to total hexosaminidase; values below approximately 5–10% of normal are diagnostic of Tay-Sachs disease. Carriers typically show intermediate ratios of 40–60% of normal.

An important technical nuance is that serum assays are unreliable during pregnancy. In pregnancy a heat-stable hexosaminidase form (called hexosaminidase I or P) rises in the blood, and the relative amounts of the other forms shift as pregnancy advances (Nakagawa and colleagues, 1978). Serum Hex-A itself also rises through pregnancy in both carriers and non-carriers, and a 1988 study could not fully separate the two groups even at the same stage of pregnancy, concluding that serum testing in pregnancy is unreliable for screening (Ben-Yoseph and colleagues). For pregnant women, testing of blood cells — the leukocyte (white blood cell, WBC) enzyme assay, or the platelet assay described as reliable in pregnancy by Nakagawa and colleagues — is used instead. The heat-stability method separates Hex-A (heat-labile at 50°C) from Hex-B (heat-stable) and is used in routine serum testing; leukocyte assay using the fluorogenic substrate 4-methylumbelliferyl-beta-N-acetylglucosaminide-6-sulphate (MUGS), which is specifically cleaved by Hex-A but not Hex-B, is preferred for diagnostic and prenatal confirmation.

Molecular genetic testing of the HEXA gene complements enzyme assays. More than 150 pathogenic variants have been identified. In the Ashkenazi Jewish population, three mutations are common: the c.1274_1277dup (4-base pair insertion in exon 11, also written 1278insTATC) causing a frameshift and premature stop codon — associated with the infantile form — a splice-site change in intron 12 (IVS12+1G>C), and c.805G>A (p.Gly269Ser, G269S) associated with adult/chronic Tay-Sachs. In French Canadians of Quebec, a 1986 study found a deletion of about 5 to 8 kilobases at the start (5′ end) of the HEXA gene. For prenatal diagnosis, chorionic villus sampling (CVS) at 10–12 weeks or amniocentesis at 15–18 weeks allows enzyme assay and/or mutation analysis on fetal tissue when both parents are confirmed carriers. Preimplantation genetic testing (PGT) is an option for couples undergoing in vitro fertilisation (IVF).

Back to Table of Contents

Neuroimaging and Electrophysiology

Brain magnetic resonance imaging (MRI) findings in infantile Tay-Sachs have a characteristic pattern that supports the clinical diagnosis when enzyme activity is not immediately available. In the first year of life, T2 and fluid-attenuated inversion recovery (FLAIR) sequences demonstrate increased signal intensity in the thalami — particularly the pulvinar and mediodorsal nuclei — and the basal ganglia (caudate and putamen). This "thalamic signal abnormality" or hyperintense thalami on T2-weighted imaging is highly characteristic, arising from the heavy neuronal density and GM2 accumulation in these structures. The cerebral cortex initially appears normal, but as disease progresses, diffuse cerebral atrophy becomes prominent along with progressive white matter signal changes (hypomyelination followed by demyelination). In later stages, severe cortical atrophy, thinning of the corpus callosum, and cerebellar atrophy are visible. The thalamic T2 hyperintensity stands in contrast to Sandhoff disease, where thalamic changes may be less prominent.

In adult Tay-Sachs disease, brain magnetic resonance imaging shows cerebellar atrophy — often the most striking finding — with variable degrees of cerebral atrophy, white matter T2 signal changes in cerebellar peduncles and brainstem, and sometimes anterior horn cell loss detectable as T2 signal changes in the spinal cord anterior horns. Magnetic resonance imaging of the spine may demonstrate cord atrophy at cervical and thoracic levels corresponding to motor neuron degeneration. These findings, though non-specific individually, in combination with the clinical presentation of motor neuron disease plus psychiatric symptoms, are the setting in which Hex-A enzyme testing is used to confirm or rule out the diagnosis.

Electroencephalography (EEG) in infantile Tay-Sachs shows characteristic abnormalities. Early in the disease, background activity may be relatively preserved, but as seizures emerge, multifocal spikes and spike-wave complexes appear. Infantile spasms, when present, are accompanied by the hypsarrhythmia pattern on electroencephalogram. Progressive electroencephalogram disorganization parallels clinical deterioration. In juvenile Tay-Sachs, electroencephalogram may show progressive slowing with multifocal discharges; photoparoxysmal responses (light-induced spike-wave discharges) occur in some patients and reflect occipital cortex hyperexcitability. Electromyography (EMG) and nerve conduction studies in adult Tay-Sachs document the lower motor neuron pathology: reduced motor unit recruitment, fibrillation potentials, and fasciculation potentials in limb muscles, with normal or near-normal nerve conduction velocities — distinguishing the anterior horn cell degeneration from peripheral neuropathy.

Back to Table of Contents

Treatment: Symptomatic and Emerging Therapies

No disease-modifying therapy is currently approved for Tay-Sachs disease, and clinical management remains supportive and symptomatic. For families of children with infantile Tay-Sachs, honest and compassionate communication about prognosis, integration of palliative care, and meticulous attention to quality of life are the foundations of management.

Seizure management is central to the care of infantile and juvenile patients. Seizure control is often partial at best but can improve comfort and reduce distress. Infantile spasms may respond to adrenocorticotropic hormone (ACTH), vigabatrin, or the ketogenic diet. As the disease progresses, multiple antiepileptic drugs (AEDs) are typically required; combinations including valproate, levetiracetam, clonazepam, and clobazam are commonly used. Seizure type evolution throughout disease course requires ongoing reassessment of the AED regimen.

Pulmonary and nutritional care becomes increasingly critical as swallowing dysfunction progresses. Aspiration risk is high and aspiration pneumonia is a leading cause of death. Chest physiotherapy, postural management, and suction equipment are standard parts of care. Gastrostomy tube (G-tube) placement allows safe enteral nutrition and medication delivery when oral feeding becomes unsafe; the timing of this decision requires careful discussion with the family, weighing burdens and benefits within a palliative framework. Baclofen may reduce muscle tone and improve comfort. Glycopyrrolate or hyoscine can manage secretions in the later stages.

Substrate reduction therapy (SRT) with miglustat (N-butyldeoxynojirimycin, an imino sugar that inhibits glucosylceramide synthase) was explored in Tay-Sachs as a potential approach to reduce upstream GM2 synthesis. Early clinical experience was disappointing; miglustat has not demonstrated meaningful clinical benefit in infantile Tay-Sachs and is not approved for this indication. Second-generation SRT agents with higher selectivity for GM2 pathway synthesis are under investigation.

Gene therapy represents the most promising avenue for future treatment. Adeno-associated virus (AAV) vectors of the rh8 type (AAVrh8) have been used to deliver functional HEXA and HEXB genes together (since functional Hex-A requires both subunits). Animal studies in cats and mice with naturally occurring Hex deficiency demonstrated dramatic neurological rescue, restoration of enzyme activity in the central nervous system (CNS), and prolonged survival. In a 2022 expanded-access report, two infants received an equal mix of AAVrh8-HEXA and AAVrh8-HEXB into the spinal fluid (one also into both thalami); the injections were well tolerated with no vector-related adverse events, but in the younger child disease progression was evident 6 months after treatment. Intrathecal administration may reach affected spinal cord motor neurons important in adult and juvenile disease. Challenges include immunogenicity of AAV capsid proteins, achieving adequate transduction of the entire neuraxis, and the difficulty of reversing established neuronal damage.

First phase 1/2 gene-therapy results (2025): Nine children with Tay-Sachs or Sandhoff disease (six infantile, three juvenile) received the dual AAVrh8 vectors injected into both thalami plus the spinal fluid, at doses doubled between four groups (Eichler and colleagues). Enzyme activity and GM2 levels improved with dose, but the correction was greatest at 12 weeks and declining by 24 weeks. The infants stayed broadly stable and kept feeding by mouth without aspiration until 3–3.5 years of age, and their seizures started later and were milder. The juvenile patients developed worsening dystonia (abnormal muscle contractions) and were excluded from further enrollment.

N-acetyl-L-leucine: In a 2023 open-label trial, 30 people aged 6 to 55 with Tay-Sachs or Sandhoff disease took this oral modified amino acid for 6 weeks. Blinded reviewers watching videos of a walking test or a hand-skill (peg-board) test rated a small improvement (p = 0.039), with no serious adverse reactions. The authors rate this as Class IV evidence, the lowest level, and the trial had no placebo group.

Pyrimethamine: In 9 adults with late-onset Tay-Sachs (2011), the old antimalarial drug pyrimethamine raised white-blood-cell Hex-A activity in every patient, by an average of 78% over baseline. The best dose varied widely (6.25–75 mg a day, average 30 mg); doses above it lost the effect, and 3 patients had more falls at higher doses, which reversed. Speech improved in 4 of the 9, but the authors wrote that clear neurological and psychiatric effects were difficult to discern because follow-up was short and patients varied widely.

Back to Table of Contents

Carrier Screening and Prevention

The population genetics of Tay-Sachs disease in the Ashkenazi Jewish community — with a carrier frequency of approximately 1 in 30 and a disease incidence (before screening) of approximately 1 in 3,600 live births — made it an ideal candidate for population-wide carrier screening. In 1969, Shintaro Okada and John O'Brien discovered that Hex-A activity could be reliably measured in peripheral blood, enabling carrier identification without genetic testing. The first organized community carrier screening programs began in North America in 1971, targeting the Ashkenazi Jewish community. Over the following decades, carrier screening became routine practice. An international review of testing centres (Kaback and colleagues, 1993) reported that nearly 1 million young adults had been tested, more than 36,000 carriers and 1,056 at-risk couples identified, and 2,416 at-risk pregnancies monitored by amniocentesis or chorionic villus sampling, with a dramatic decrease in the incidence of Tay-Sachs disease in Jewish populations. This program is widely cited as a landmark success in applied medical genetics.

Current guidelines recommend carrier screening before or early in pregnancy for individuals of Ashkenazi Jewish, French-Canadian, Cajun, or Irish descent. Pan-ethnic screening is increasingly offered to all couples given the widespread availability of expanded carrier screening panels. The preferred screening test is now molecular genetic testing (mutation panel covering the common pathogenic variants for the targeted population, plus full sequencing for individuals whose ethnic background includes other risk groups), supplemented by enzyme activity measurement when a variant of uncertain significance is identified. Enzyme activity alone is less reliable as a first-tier screen than was thought in the early screening era, because some carriers — particularly those with pseudodeficiency alleles (variants that reduce enzyme activity in vitro but do not cause disease) — can have activity levels in the carrier range, generating false positives for carrier status. A 2019 analysis estimated that sequencing the whole coding region of HEXA had higher clinical sensitivity, specificity and positive predictive value than the Hex-A enzyme test in both Ashkenazi Jewish and other populations; the differences were significant for every comparison except sensitivity in Ashkenazi Jewish people. Several of its authors were employees of a laboratory that performs carrier screening.

When both members of a couple are confirmed carriers, options include: continued pregnancy with prenatal diagnosis by CVS or amniocentesis (enzyme assay and/or mutation analysis on fetal tissue); preimplantation genetic testing (PGT) using IVF with embryo biopsy and selection of unaffected embryos before implantation; use of donor gametes; adoption; or accepting the 25% per-pregnancy risk. Genetic counseling for carrier couples typically covers the full spectrum of disease (infantile to adult onset), recurrence risk in subsequent pregnancies and extended family, options for future pregnancies, and the distinction between carrier status and disease.

Back to Table of Contents

Key Research Papers

  1. Kaback M, Lim-Steele J, Dabholkar D, et al. Tay-Sachs disease — carrier screening, prenatal diagnosis, and the molecular era. JAMA. 1993;270(19):2307-2315. — PubMed PMID: 8230592
  2. Gravel RA, et al. The GM2 gangliosidoses. In: Scriver CR, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. McGraw-Hill; 2001. Chapter 153.
  3. Johnson WG. The clinical spectrum of hexosaminidase deficiency diseases. Neurology. 1981;31(11):1453-1456. — Search PubMed
  4. Neudorfer O, et al. Late-onset Tay-Sachs disease: phenotypic characterization and genotypic correlations in 21 affected patients. Genet Med. 2005;7(2):119-123. — PubMed PMID: 15714079
  5. Okada S, O'Brien JS. Tay-Sachs disease: generalized absence of a beta-D-N-acetylhexosaminidase component. Science. 1969;165(3894):698-700. — PubMed PMID: 5793973
  6. Cachon-Gonzalez MB, et al. Effective gene therapy in an authentic model of Tay-Sachs-related diseases. Proc Natl Acad Sci USA. 2006;103(27):10373-10378. — PubMed PMID: 16801539
  7. Osher E, Fattal-Valevski A, Sagie L, et al. Pyrimethamine increases β-hexosaminidase A activity in patients with Late Onset Tay Sachs. Mol Genet Metab. 2011;102(3):356-363. — PubMed PMID: 21185210
  8. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D. Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients (cell-culture study). J Biol Chem. 2004;279(14):13478-13487. — PubMed PMID: 14724290
  9. Tifft CJ, Proia RL. Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases. Glycobiology. 2000;10(12):1249-1258. — PubMed PMID: 11159916
  10. Lui F, Ramani PK, Parayil Sankaran B. Tay-Sachs Disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. — PubMed PMID: 33232090
  11. Myerowitz R, Hogikyan ND. Different mutations in Ashkenazi Jewish and non-Jewish French Canadians with Tay-Sachs disease. Science. 1986;232(4758):1646-1648. — PubMed PMID: 3754980
  12. Ward CP, Fensom AH, Green PM. Biallelic discrimination assays for the three common Ashkenazi Jewish mutations and a common non-Jewish mutation, in Tay-Sachs disease, using fluorogenic TaqMan probes. Genet Test. 2000;4(4):351-358. — PubMed PMID: 11216658
  13. Nakagawa S, Kumin S, Chandra P, Nitowsky HM. Human hexosaminidase isozymes. Assay of platelet activity for heterozygote identification during pregnancy. Clin Chim Acta. 1978;88(2):249-256. — PubMed PMID: 699320
  14. Ben-Yoseph Y, Pack BA, Thomas PM, Nadler HL, Kaback MM. Maternal serum hexosaminidase A in pregnancy: effects of gestational age and fetal genotype. Am J Med Genet. 1988;29(4):891-899. — PubMed PMID: 2969680
  15. Flotte TR, Cataltepe O, Puri A, et al. AAV gene therapy for Tay-Sachs disease. Nat Med. 2022;28(2):251-259. — PubMed PMID: 35145305
  16. Eichler F, Cataltepe OI, Daci R, et al. Dual-vector rAAVrh8 gene therapy for GM2 gangliosidosis: a phase 1/2 trial. Nat Med. 2025;31(9):2927-2935. — PubMed PMID: 40817303
  17. Martakis K, Claassen J, Gascon-Bayari J, et al. Efficacy and safety of N-acetyl-l-leucine in children and adults with GM2 gangliosidoses. Neurology. 2023;100(10):e1072-e1083. — PubMed PMID: 36456200
  18. Drousiotou A, Stylianidou G, Anastasiadou V, et al. Sandhoff disease in Cyprus: population screening by biochemical and DNA analysis indicates a high frequency of carriers in the Maronite community. Hum Genet. 2000;107(1):12-17. — PubMed PMID: 10982028
  19. Fitterer B, Hall P, Antonishyn N, Desikan R, Gelb M, Lehotay D. Incidence and carrier frequency of Sandhoff disease in Saskatchewan determined using a novel substrate with detection by tandem mass spectrometry and molecular genetic analysis. Mol Genet Metab. 2014;111(3):382-389. — PubMed PMID: 24461908
  20. Kleiman FE, de Kremer RD, de Ramirez AO, Gravel RA, Argaraña CE. Sandhoff disease in Argentina: high frequency of a splice site mutation in the HEXB gene and correlation between enzyme and DNA-based tests for heterozygote detection. Hum Genet. 1994;94(3):279-282. — PubMed PMID: 8076944
  21. Cecchi AC, Vengoechea ES, Kaseniit KE, et al. Screening for Tay-Sachs disease carriers by full-exon sequencing with novel variant interpretation outperforms enzyme testing in a pan-ethnic cohort. Mol Genet Genomic Med. 2019;7(8):e836. — PubMed PMID: 31293106

Back to Table of Contents

Connections